Search
Search Results
-
Liraglutide Improves PCOS Symptoms in Rats by Targeting FDX1
BackgroundPolycystic ovary syndrome (PCOS) is a gynecological endocrine disorder characterized by ovulatory disorders, hyperandrogenemia, and...
-
Liraglutide Suppresses Myocardial Fibrosis Progression by Inhibiting the Smad Signaling Pathway
ObjectiveLiraglutide is a commonly used hypoglycemic agent in clinical practice, and has been demonstrated to have protective effects against the...
-
Efficacy and Safety of a Biosimilar Liraglutide (Melitide®) Versus the Reference Liraglutide (Victoza®) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial
IntroductionLiraglutide effectively controls blood glucose level and reduces body weight. The aim of this study was to compare the efficacy and...
-
Liraglutide induced browning of visceral white adipose through regulation of miRNAs in high-fat-diet-induced obese mice
ObjectiveObesity is characterized by excessive accumulation of white adipose tissue (WAT). Conversely, brown adipose tissue is protective against...
-
Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery
Preoperative management of patients living with severe obesity can be challenging; in this context, the preoperative weight loss may help to obtain...
-
Liraglutide reduces plasma dihydroceramide levels in patients with type 2 diabetes
BackgroundEmerging evidence supports that dihydroceramides (DhCer) and ceramides (Cer) contribute to the pathophysiology of insulin resistance and...
-
Liraglutide improved the reproductive function of obese mice by upregulating the testicular AC3/cAMP/PKA pathway
BackgroundThe incidence of male reproductive dysfunction is increasing annually, and many studies have shown that obesity can cause severe harm to...
-
Liraglutide and not lifestyle intervention reduces soluble CD163 after comparable weight loss in obese participants with prediabetes or type 2 diabetes mellitus
BackgroundThe GLP-1 receptor agonist liraglutide is used to treat hyperglycemia in type 2 diabetes but is also known to induce weight loss, preserve...
-
Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database
BackgroundSemaglutide, liraglutide and tirzepatide are glucagon-like peptide-1 (GLP-1) receptor agonists that are effective for weight reduction....
-
Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation
PurposeDiastolic dysfunction is an increasingly common cardiac pathology linked to heart failure with preserved ejection fraction. Previous studies...
-
The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery
PurposeDespite the benefits of bariatric surgery for many patients, there are a proportion of patients who do not achieve adequate weight loss. We...
-
Laparoscopic adjustable gastric banding with liraglutide in adults with obesity and type 2 diabetes (GLIDE): a pilot randomised placebo controlled trial
IntroductionObesity drives type 2 diabetes (T2DM) development. Laparoscopic adjustable gastric banding (LAGB) has lower weight reduction than other...
-
Immediate Impact of Switching from Dipeptidyl Peptidase 4 (DPP4) Inhibitors to Low-Dose (0.3 mg) Liraglutide on Glucose Profiles: A Retrospective Observational Study
IntroductionAs treatment agents for diabetes, liraglutide is a long-acting glucagon-like peptide 1 receptor agonist, and dipeptidyl peptidase 4...
-
Efficacy and safety of liraglutide for weight management in children and adolescents: a systematic review and meta-analysis of randomized controlled trials
Obesity represents a risk factor for multiple coexisting conditions and complications. Liraglutide is mainly reserved for populations who fail to...
-
Efficacy of High-dose Liraglutide 3.0 mg in Patients with Poor Response to Bariatric Surgery: Real-world Experience and Updated Meta-analysis
PurposePoor response to bariatric surgery, characterized by insufficient weight loss (IWL) or weight regain (WR), poses a significant challenge in...
